Adcetris Indications/Uses

Hodgkin lymphoma: BRENTUXIMAB VEDOTIN (ADCETRIS) is indicated for adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD) (see Dosage & Administration and Pharmacology: Pharmacodynamics under Actions).
BRENTUXIMAB VEDOTIN (ADCETRIS) is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT) (see Pharmacology: Pharmacodynamics under Actions).
BRENTUXIMAB VEDOTIN (ADCETRIS) is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): following ASCT, or; following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.
Previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), in combination with chemotherapy: BRENTUXIMAB VEDOTIN (ADCETRIS) is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.
BRENTUXIMAB VEDOTIN (ADCETRIS) is indicated for the treatment of adult patients with relapsed or refractory (sALCL).
Cutaneous T-cell lymphoma: BRENTUXIMAB VEDOTIN (ADCETRIS) is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy (see Pharmacology: Pharmacodynamics under Actions).